Skip to content

Study · Animal study (in vivo) · rat · 2025

12 results

The effects of abaloparatide on alveolar bone loss in postmenopausal osteoporotic rats with periodontitis.

Kızıldağ A, Alpan AL, Özdoğan Z, Özmen Ö, Zavrak N, Terzi M

BMC oral health29 Sept 2025Cited by 2 (Europe PMC)

PMID41023931 (opens in a new tab)PMCIDPMC12482739 (opens in a new tab)DOI10.1186/s12903-025-06915-1 (opens in a new tab)PepBankPUB-41023931
Read at sourcePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In osteoporotic rats with periodontitis, abaloparatide significantly reduced alveolar bone loss in the treatment groups.

    In plain wordsIn rats with osteoporosis and periodontitis, abaloparatide reduced alveolar bone loss.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseAlveolar bone loss
    Study

    ratn: not reported in source

    ovariectomized rats with ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 or 80 µg/kg · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    Abaloparatide treatment significantly reduced ABL in the treatment groups and significantly increased BMP-2, ALP, Col-1, OPG, OCN, and CTX levels.
    2 context sentences
    Summary · context
    Forty adult female rats were divided into five equal groups: non-ligated (controls), periodontitis (P), periodontitis + osteoporosis (PO), PO treatment with 10 µg/kg abaloparatide (PO-10), and PO treatment with 80 µg/kg abaloparatide (PO-80).
    Summary · context
    All rats were sacrificed at 30 days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In osteoporotic rats with periodontitis, abaloparatide significantly increased BMP-2 levels in the treatment groups.

    In plain wordsIn rats with osteoporosis and periodontitis, abaloparatide increased BMP-2 levels.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBMP-2 levels
    Study

    ratn: not reported in source

    ovariectomized rats with ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 or 80 µg/kg · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    Abaloparatide treatment significantly reduced ABL in the treatment groups and significantly increased BMP-2, ALP, Col-1, OPG, OCN, and CTX levels.
    2 context sentences
    Summary · context
    Forty adult female rats were divided into five equal groups: non-ligated (controls), periodontitis (P), periodontitis + osteoporosis (PO), PO treatment with 10 µg/kg abaloparatide (PO-10), and PO treatment with 80 µg/kg abaloparatide (PO-80).
    Summary · context
    All rats were sacrificed at 30 days.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In osteoporotic rats with periodontitis, abaloparatide significantly increased ALP levels in the treatment groups.

    In plain wordsIn rats with osteoporosis and periodontitis, abaloparatide increased ALP levels.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseALP levels
    Study

    ratn: not reported in source

    ovariectomized rats with ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 or 80 µg/kg · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    Abaloparatide treatment significantly reduced ABL in the treatment groups and significantly increased BMP-2, ALP, Col-1, OPG, OCN, and CTX levels.
    2 context sentences
    Summary · context
    Forty adult female rats were divided into five equal groups: non-ligated (controls), periodontitis (P), periodontitis + osteoporosis (PO), PO treatment with 10 µg/kg abaloparatide (PO-10), and PO treatment with 80 µg/kg abaloparatide (PO-80).
    Summary · context
    All rats were sacrificed at 30 days.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In osteoporotic rats with periodontitis, abaloparatide significantly increased Col-1 levels in the treatment groups.

    In plain wordsIn rats with osteoporosis and periodontitis, abaloparatide increased collagen-1 levels.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCollagen-1 levels
    Study

    ratn: not reported in source

    ovariectomized rats with ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 or 80 µg/kg · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    Abaloparatide treatment significantly reduced ABL in the treatment groups and significantly increased BMP-2, ALP, Col-1, OPG, OCN, and CTX levels.
    2 context sentences
    Summary · context
    Forty adult female rats were divided into five equal groups: non-ligated (controls), periodontitis (P), periodontitis + osteoporosis (PO), PO treatment with 10 µg/kg abaloparatide (PO-10), and PO treatment with 80 µg/kg abaloparatide (PO-80).
    Summary · context
    All rats were sacrificed at 30 days.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In osteoporotic rats with periodontitis, abaloparatide significantly increased OPG levels in the treatment groups.

    In plain wordsIn rats with osteoporosis and periodontitis, abaloparatide increased OPG levels.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseOPG levels
    Study

    ratn: not reported in source

    ovariectomized rats with ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 or 80 µg/kg · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    Abaloparatide treatment significantly reduced ABL in the treatment groups and significantly increased BMP-2, ALP, Col-1, OPG, OCN, and CTX levels.
    2 context sentences
    Summary · context
    Forty adult female rats were divided into five equal groups: non-ligated (controls), periodontitis (P), periodontitis + osteoporosis (PO), PO treatment with 10 µg/kg abaloparatide (PO-10), and PO treatment with 80 µg/kg abaloparatide (PO-80).
    Summary · context
    All rats were sacrificed at 30 days.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In osteoporotic rats with periodontitis, abaloparatide significantly increased OCN levels in the treatment groups.

    In plain wordsIn rats with osteoporosis and periodontitis, abaloparatide increased osteocalcin levels.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseOsteocalcin levels
    Study

    ratn: not reported in source

    ovariectomized rats with ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 or 80 µg/kg · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    Abaloparatide treatment significantly reduced ABL in the treatment groups and significantly increased BMP-2, ALP, Col-1, OPG, OCN, and CTX levels.
    2 context sentences
    Summary · context
    Forty adult female rats were divided into five equal groups: non-ligated (controls), periodontitis (P), periodontitis + osteoporosis (PO), PO treatment with 10 µg/kg abaloparatide (PO-10), and PO treatment with 80 µg/kg abaloparatide (PO-80).
    Summary · context
    All rats were sacrificed at 30 days.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In osteoporotic rats with periodontitis, abaloparatide significantly increased CTX levels in the treatment groups.

    In plain wordsIn rats with osteoporosis and periodontitis, abaloparatide increased CTX levels.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCTX levels
    Study

    ratn: not reported in source

    ovariectomized rats with ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 or 80 µg/kg · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    Abaloparatide treatment significantly reduced ABL in the treatment groups and significantly increased BMP-2, ALP, Col-1, OPG, OCN, and CTX levels.
    2 context sentences
    Summary · context
    Forty adult female rats were divided into five equal groups: non-ligated (controls), periodontitis (P), periodontitis + osteoporosis (PO), PO treatment with 10 µg/kg abaloparatide (PO-10), and PO treatment with 80 µg/kg abaloparatide (PO-80).
    Summary · context
    All rats were sacrificed at 30 days.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In osteoporotic rats with periodontitis, 80 µg/kg abaloparatide significantly modulated RANKL, OPG and CTX levels without stated dose-specific directions.

    In plain wordsIn rats with osteoporosis and periodontitis, high-dose abaloparatide changed RANKL, OPG and CTX levels without stated dose-specific directions.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Direction not reportedRANKL, OPG and CTX modulation at high dose
    Study

    ratn: not reported in source

    ovariectomized rats with ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 µg/kg · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    In particular, 80 µg/kg abaloparatide treatment significantly modulated the RANKL, OPG, and CTX levels in the PO-80 group.
    2 context sentences
    Summary · context
    Forty adult female rats were divided into five equal groups: non-ligated (controls), periodontitis (P), periodontitis + osteoporosis (PO), PO treatment with 10 µg/kg abaloparatide (PO-10), and PO treatment with 80 µg/kg abaloparatide (PO-80).
    Summary · context
    All rats were sacrificed at 30 days.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In osteoporotic rats with periodontitis, abaloparatide significantly increased bone percentage on micro-CT.

    In plain wordsIn rats with osteoporosis and periodontitis, abaloparatide increased the percentage of bone on imaging.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBone percentage
    Study

    ratn: not reported in source

    ovariectomized rats with ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 or 80 µg/kg · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    The micro-CT results indicated that abaloparatide treatment significantly enhanced the percentage of bone, trabecular thickness, trabecular number, and bone surface density.
    2 context sentences
    Summary · context
    Forty adult female rats were divided into five equal groups: non-ligated (controls), periodontitis (P), periodontitis + osteoporosis (PO), PO treatment with 10 µg/kg abaloparatide (PO-10), and PO treatment with 80 µg/kg abaloparatide (PO-80).
    Summary · context
    All rats were sacrificed at 30 days.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In osteoporotic rats with periodontitis, abaloparatide significantly increased trabecular thickness.

    In plain wordsIn rats with osteoporosis and periodontitis, abaloparatide increased spongy bone thickness.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTrabecular thickness
    Study

    ratn: not reported in source

    ovariectomized rats with ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 or 80 µg/kg · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    The micro-CT results indicated that abaloparatide treatment significantly enhanced the percentage of bone, trabecular thickness, trabecular number, and bone surface density.
    2 context sentences
    Summary · context
    Forty adult female rats were divided into five equal groups: non-ligated (controls), periodontitis (P), periodontitis + osteoporosis (PO), PO treatment with 10 µg/kg abaloparatide (PO-10), and PO treatment with 80 µg/kg abaloparatide (PO-80).
    Summary · context
    All rats were sacrificed at 30 days.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In osteoporotic rats with periodontitis, abaloparatide significantly increased trabecular number.

    In plain wordsIn rats with osteoporosis and periodontitis, abaloparatide increased the number of bone trabeculae.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTrabecular number
    Study

    ratn: not reported in source

    ovariectomized rats with ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 or 80 µg/kg · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    The micro-CT results indicated that abaloparatide treatment significantly enhanced the percentage of bone, trabecular thickness, trabecular number, and bone surface density.
    2 context sentences
    Summary · context
    Forty adult female rats were divided into five equal groups: non-ligated (controls), periodontitis (P), periodontitis + osteoporosis (PO), PO treatment with 10 µg/kg abaloparatide (PO-10), and PO treatment with 80 µg/kg abaloparatide (PO-80).
    Summary · context
    All rats were sacrificed at 30 days.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In osteoporotic rats with periodontitis, abaloparatide significantly increased bone surface density.

    In plain wordsIn rats with osteoporosis and periodontitis, abaloparatide increased bone surface density.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBone surface density
    Study

    ratn: not reported in source

    ovariectomized rats with ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 or 80 µg/kg · 30 daysAs given in this study (rat).

    Source sentences

    Summary
    The micro-CT results indicated that abaloparatide treatment significantly enhanced the percentage of bone, trabecular thickness, trabecular number, and bone surface density.
    2 context sentences
    Summary · context
    Forty adult female rats were divided into five equal groups: non-ligated (controls), periodontitis (P), periodontitis + osteoporosis (PO), PO treatment with 10 µg/kg abaloparatide (PO-10), and PO treatment with 80 µg/kg abaloparatide (PO-80).
    Summary · context
    All rats were sacrificed at 30 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.